News and Updates
iVeena announces the initiation of its Phase I/2b in-human pilot clinical study for IVMED-10, a bioerodable implant designed to eliminate the need for eye drops after cataract surgery.
On Monday, May 30th, iVeena initiated the Phase I/2a pilot clinical study for IVMED-10. This product is a bioerodable dexamethasone implant given at the time of cataract surgery that releases the drug
iVeena to present at the BioTech Showcase Conference that runs in parallel with the JP Morgan Conference in San Francisco on Wednesday, January 11, 2017
iVeena to present at the BioTech Showcase Conference that runs in parallel with the JP Morgan Conference in San Francisco on Wednesday, January 11, 2017
iVeena has been awarded a $150K 2017 USTAR Technology Acceleration Grant to advance development of IVMED-70, our innovative Glaucoma MIGS (Minimally Invasive Glaucoma Stent) device.
Glaucoma affects approximately three million individuals in the US and can lead to blindness if not treated. The current standard of care is to administer eye drops on a daily basis that results in a
iVeena appoints Peter Hnik, MD, MHSc as Chief Medical Officer to oversee expanding clinical program.
Dr. Peter Hnik Appointed Chief Medical Officer Peter Hnik, MD, MHSc has been appointed Chief Medical officer of iVeena Delivery Systems Inc. Dr. Hnik will oversee the expansion of the iVeena clinica
iVeena announces the appointment of Alan Crandall, M.D. to the iVeena Scientific Advisory Board to expand its Glaucoma program
Alan Crandall, M.D. is considered a world authority in the research and treatment of glaucoma. Dr. Crandall has chaired more than 150 major national and international symposia. He has co-authored two
Page 6 of 9